Belantamab mafodotin
- Generic Name
- Belantamab mafodotin
- Brand Names
- BLENREP
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2050232-20-5
- Unique Ingredient Identifier
- DB1041CXDG
- Background
Belantamab mafodotin, or GSK2857916, is an afucosylated monoclonal antibody that targets B cell maturation antigen conjugated to the microtubule disrupter monomethyl auristatin-F (MMAF).
...
- Indication
Belantamab mafodotin is indicated in the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.
- Associated Conditions
- Relapsed/Refractory Multiple Myeloma (RRMM)
- Associated Therapies
- -
Blenrep (belantamab mafodotin) in combination receives Breakthrough Therapy
GSK's Blenrep receives Breakthrough Therapy Designation in China for relapsed or refractory multiple myeloma treatment based on DREAMM-7 trial results, showing significant PFS improvements over standard care.
Blenrep Combination Receives Breakthrough Therapy Designation For Multiple
GSK's Blenrep granted Breakthrough Therapy Designation in China for relapsed or refractory multiple myeloma treatment, based on DREAMM-7 trial results.
GSK myeloma treatment given breakthrough therapy designation in China
GSK granted breakthrough therapy designation in China for Blenrep, a treatment for relapsed or refractory multiple myeloma, based on DREAMM-7 trial results.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath